Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-AC12-GGGC
- Development stage
- Preclinical
- Lead developer
- Uppsala University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[99mTc]Tc-AC12-GGGC is a technetium-99m (99mTc) labeled affibody-based imaging tracer designed for the detection and molecular imaging of B7-H3 (CD276) expressing tumors. The agent consists of the high-affinity anti-B7-H3 affibody molecule AC12, fused at its C-terminus to a peptide-based cysteine-containing triglycine-cysteine (-GGGC) chelator, which coordinates the gamma-emitting radionuclide 99mTc. B7-H3 is an immune checkpoint transmembrane protein overexpressed in various human malignancies, including ovarian and breast cancers, while showing low expression in normal tissues. Preclinical studies of [99mTc]Tc-AC12-GGGC demonstrate rapid blood clearance and high tumor-to-blood contrast, indicating its potential as a SPECT/CT imaging agent for patient stratification in B7-H3-targeted therapies.
- Other names
- 99mTc-AC12-GGGCtechnetium-99m-labeled AC12-GGGCtechnetium99m-labeled AC12-GGGCtechnetium 99m-labeled AC12-GGGC
02
Targets
B7-H3
Beyond the preview
Go deeper on [99mTc]Tc-AC12-GGGC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]Tc-AC12-GGGC.